Literature DB >> 26254483

Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

Mami Suzuki1, Ayaka Yamanoi2, Yusuke Machino2, Michiko Ootsubo2, Ken-ichi Izawa2, Junya Kohroki2, Yasuhiko Masuho2.   

Abstract

The Fc domain of human IgG1 binds to Fcγ receptors (FcγRs) to induce effector functions such as phagocytosis. There are four interchain disulfide bonds between the H and L chains. In this study, the disulfide bonds within the IgG1 trastuzumab (TRA), which is specific for HER2, were cleaved by mild S-sulfonation or by mild reduction followed by S-alkylation with three different reagents. The cleavage did not change the binding activities of TRA to HER2-bearing SK-BR-3 cells. The binding activities of TRA to FcγRIIA and FcγRIIB were greatly enhanced by modification with mild reduction and S-alkylation with ICH2CONH2 or N-(4-aminophenyl) maleimide, while the binding activities of TRA to FcγRI and FcγRIIIA were decreased by any of the four modifications. However, the interchain disulfide bond cleavage by the different modifications did not change the antibody-dependent cell-mediated phagocytosis (ADCP) of SK-BR-3 cells by activated THP-1 cells. The order of FcγR expression levels on the THP-1 cells was FcγRII > FcγRI > FcγRIII and ADCP was inhibited by blocking antibodies against FcγRI and FcγRII. These results imply that the effect of the interchain disulfide bond cleavage on FcγRs binding and ADCP is dependent on modifications of the cysteine residues and the FcγR isotypes.
© The Authors 2015. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  Fcγ receptors; IgG1; interchain disulfide bonds; phagocytosis; trastuzumab

Mesh:

Substances:

Year:  2015        PMID: 26254483      PMCID: PMC4882641          DOI: 10.1093/jb/mvv074

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  31 in total

1.  Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.

Authors:  P Sondermann; J Kaiser; U Jacob
Journal:  J Mol Biol       Date:  2001-06-08       Impact factor: 5.469

Review 2.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

3.  Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.

Authors:  Hiroaki Nagashima; Michiko Ootsubo; Mizuki Fukazawa; Sotaro Motoi; Shu Konakahara; Yasuhiko Masuho
Journal:  J Biosci Bioeng       Date:  2011-01-06       Impact factor: 2.894

4.  Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells.

Authors:  Susheela Tridandapani; Kristina Siefker; Jean-Luc Teillaud; Jo Ellen Carter; Mark D Wewers; Clark L Anderson
Journal:  J Biol Chem       Date:  2001-12-07       Impact factor: 5.157

Review 5.  Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.

Authors:  Gonzalo Recondo; Enrique Dìaz Canton; Màximo de la Vega; Martin Greco; Gonzalo Recondo; Matias E Valsecchi
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).

Authors:  Emily L Williams; Alison L Tutt; Ruth R French; H T Claude Chan; Betty Lau; Christine A Penfold; C Ian Mockridge; Ali Roghanian; Kerry L Cox; J Sjef Verbeek; Martin J Glennie; Mark S Cragg
Journal:  Eur J Immunol       Date:  2012-07-04       Impact factor: 5.532

7.  Reduction of disulfide bonds within anti-D results in enhanced Fcgamma receptor blockade.

Authors:  Andrew S Kruspe; Yulia Katsman; Darinka Sakac; Cécile Chagneau; Anna Glistvain; Richard F Langler; Donald R Branch
Journal:  Transfusion       Date:  2009-01-02       Impact factor: 3.157

8.  Neutrophils mediate antibody-induced antitumor effects in mice.

Authors:  Marcello Albanesi; David A Mancardi; Friederike Jönsson; Bruno Iannascoli; Laurence Fiette; James P Di Santo; Clifford A Lowell; Pierre Bruhns
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

9.  Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).

Authors:  Y Machino; H Ohta; E Suzuki; S Higurashi; T Tezuka; H Nagashima; J Kohroki; Y Masuho
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

Review 10.  Therapeutic human monoclonal antibodies against cancer.

Authors:  Jamie Jarboe; Anumeha Gupta; M W Saif
Journal:  Methods Mol Biol       Date:  2014
View more
  2 in total

Review 1.  Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins.

Authors:  Jude C Lakbub; Joshua T Shipman; Heather Desaire
Journal:  Anal Bioanal Chem       Date:  2017-12-18       Impact factor: 4.142

2.  The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies.

Authors:  Shalom A Gurjar; Jun X Wheeler; Meenu Wadhwa; Robin Thorpe; Ian Kimber; Jeremy P Derrick; Rebecca J Dearman; Clive Metcalfe
Journal:  J Biol Chem       Date:  2019-11-14       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.